Research library / GLP-1 drugs

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

J Cummings, A Atri, M Sano, H Zetterberg, P Scheltens, F Knop et al.. The Lancet. 2026.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

EVOKE and EVOKE+: oral semaglutide did not slow early Alzheimer's disease progression.

Limits

Manufacturer funded.

Source

doi.org/10.1016/S0140-6736(26)00459-9 · PubMed 41865758

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.